RxDoctor Payments Data

Susan Yahia, DO

Internal Medicine · Miami, FLNPI 1396759601

Payments from drug & device makers

$1,567in general payments, 2019–2025

Across 68 payments — averaging $23.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$333
  • Lilly USA, LLC$292
  • Pfizer$179
  • Inspire Medical Systems, Inc.$172
  • Esperion Therapeutics, Inc.$170
  • Amgen$94
  • plus $328 from 7 others

What the payments were for

  • Food & beverage$1,567100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,567 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$83,955
Medicare patients
145
Services billed
1,380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide27$35,874
FarxigaDapagliflozin Propanediol22$28,628
RybelsusSemaglutide13$16,635
EliquisApixaban16$15,249
JardianceEmpagliflozin14$11,864
SynthroidLevothyroxine Sodium38$2,996
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,664
Amlodipine Besylate146$1,126
Valsartan28$991
Atorvastatin Calcium111$983
Levothyroxine Sodium84$866
Metoprolol Succinate80$865
Escitalopram Oxalate40$782
Rosuvastatin Calcium139$728
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$672

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$333$52,50840 claims
PfizerEliquis$179$15,24916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →